These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 15023054

  • 1. Evidence for the proximity of the extreme N-terminus of the neurokinin-2 (NK2) tachykinin receptor to Cys167 in the putative fourth transmembrane helix.
    Bhogal N, Blaney FE, Ingley PM, Rees J, Findlay JB.
    Biochemistry; 2004 Mar 23; 43(11):3027-38. PubMed ID: 15023054
    [Abstract] [Full Text] [Related]

  • 2. The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors.
    Xu W, Chen C, Huang P, Li J, de Riel JK, Javitch JA, Liu-Chen LY.
    Biochemistry; 2000 Nov 14; 39(45):13904-15. PubMed ID: 11076532
    [Abstract] [Full Text] [Related]

  • 3. MTSEA prevents ligand binding to the human melanocortin-4 receptor by modification of cysteine 130 in transmembrane helix 3.
    Cox A, Donnelly D, Kaur M, Cheetham SC, Cockcroft VB, Findlay JB.
    FEBS Lett; 2005 Jan 03; 579(1):285-91. PubMed ID: 15620728
    [Abstract] [Full Text] [Related]

  • 4. Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonists.
    Meini S, Bellucci F, Catalani C, Cucchi P, Patacchini R, Rotondaro L, Altamura M, Giuliani S, Giolitti A, Maggi CA.
    Eur J Pharmacol; 2004 Mar 19; 488(1-3):61-9. PubMed ID: 15044036
    [Abstract] [Full Text] [Related]

  • 5. Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor.
    Marjamäki A, Frang H, Pihlavisto M, Hoffrén AM, Salminen T, Johnson MS, Kallio J, Javitch JA, Scheinin M.
    J Biol Chem; 1999 Jul 30; 274(31):21867-72. PubMed ID: 10419505
    [Abstract] [Full Text] [Related]

  • 6. Selected cysteine residues in transmembrane domains of mu-opioid receptor are critical for effects of sulfhydryl reagents.
    Deng HB, Guang W, Wang JB.
    J Pharmacol Exp Ther; 2000 Apr 30; 293(1):113-20. PubMed ID: 10734160
    [Abstract] [Full Text] [Related]

  • 7. Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis.
    Martin SS, Boucard AA, Clément M, Escher E, Leduc R, Guillemette G.
    J Biol Chem; 2004 Dec 03; 279(49):51415-23. PubMed ID: 15452107
    [Abstract] [Full Text] [Related]

  • 8. The fourth transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle.
    Javitch JA, Shi L, Simpson MM, Chen J, Chiappa V, Visiers I, Weinstein H, Ballesteros JA.
    Biochemistry; 2000 Oct 10; 39(40):12190-9. PubMed ID: 11015197
    [Abstract] [Full Text] [Related]

  • 9. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment.
    Javitch JA, Ballesteros JA, Chen J, Chiappa V, Simpson MM.
    Biochemistry; 1999 Jun 22; 38(25):7961-8. PubMed ID: 10387039
    [Abstract] [Full Text] [Related]

  • 10. The ligand binding site of the neurokinin 2 receptor. Site-directed mutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor.
    Bhogal N, Donnelly D, Findlay JB.
    J Biol Chem; 1994 Nov 04; 269(44):27269-74. PubMed ID: 7961636
    [Abstract] [Full Text] [Related]

  • 11. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template.
    Zhang R, Hurst DP, Barnett-Norris J, Reggio PH, Song ZH.
    Mol Pharmacol; 2005 Jul 04; 68(1):69-83. PubMed ID: 15840841
    [Abstract] [Full Text] [Related]

  • 12. Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor.
    Meini S, Bellucci F, Catalani C, Cucchi P, Giolitti A, Santicioli P, Giuliani S.
    J Pharmacol Exp Ther; 2009 May 04; 329(2):486-95. PubMed ID: 19218528
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.
    Bellucci F, Meini S, Catalioto RM, Catalani C, Giuliani S, Quartara L, Giolitti A, Faiella A, Rotondaro L, Candenas ML, Pinto FM, Maggi CA.
    Eur J Pharmacol; 2004 Sep 24; 499(3):229-38. PubMed ID: 15381044
    [Abstract] [Full Text] [Related]

  • 16. Cysteine 144 in the third transmembrane domain of the creatine transporter is located close to a substrate-binding site.
    Dodd JR, Christie DL.
    J Biol Chem; 2001 Dec 14; 276(50):46983-8. PubMed ID: 11598117
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Use of an in situ disulfide cross-linking strategy to map proximities between amino acid residues in transmembrane domains I and VII of the M3 muscarinic acetylcholine receptor.
    Hamdan FF, Ward SD, Siddiqui NA, Bloodworth LM, Wess J.
    Biochemistry; 2002 Jun 18; 41(24):7647-58. PubMed ID: 12056896
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.